🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease

RecruitingNAAges 18 Years - anyAllBritish Columbia Cancer Agency
NCT05257967 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life. With improvement in treatment options, rates of leptomeningeal disease are increasing and currently found in up to 9% of EGFR mutant NSCLC. Systemic therapy may be more effective if it can target the correct molecular aberration. The molecular characterization of central nervous system disease may differ from disease outside of the central nervous system. The aim of this pilot trial is to evaluate for molecular differences between cerebral spinal fluid (CSF) and blood circulating tumor DNA (ctDNA) through the use of ddPCR and BC Cancer NGS panel molecular testing.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Subject age is greater than or equal to 18 years at the time of signature of informed consent. * Histologically or cytologically confirmed metastatic EGFR mutant NSCLC. * Leptomeningeal disease based on brain MRI or CSF cytology. * ECOG 0-3. * Life expectancy of at least 8 weeks. * Adequate hematologic and end organ function for testing. * Ability to give informed consent for the study procedures defined in this protocol. Exclusion Criteria: * Inability to undergo a lumbar puncture due to thrombocytopenia, bleeding disorders, as well as inability to cooperate or consent to procedure. * Subjects who are otherwise felt by the treating clinician to be unfit to proceed with this protocol. * MRI spine demonstrating spinal leptomeningeal disease preventing a safe lumbar puncture.
💊

What it tests

  • Lumbar puncture and Phlebotomy
📍

Where

1 site
BC Cancer
Vancouver, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy